Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.alembicpharmaceuticals.com | |
Market Cap | 19,305.45 Cr. | |
Enterprise Value(EV) | 19,975.44 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 30.03 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 32.71 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.15 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 236.59 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 4.15 | Calculated using Price: 982.15 |
Dividend Yield | 0.81 | Period Ending 2023-03 |
No. of Shares Subscribed | 19.66 Cr. | 196,563,124 Shares |
FaceValue | 2 | |
About Alembic Pharmaceuticals Ltd. | ||
The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments. |
1 Day |
|
+0.44% |
1 Week |
|
+4.61% |
1 Month |
|
-5.83% |
3 Month |
|
+28.54% |
6 Month |
|
+30.28% |
1 Year |
|
+102.24% |
2 Year |
|
+30.55% |
5 Year |
|
+86.93% |
10 Year |
|
+246.37% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 36.24 | 58.02 | 23.25 | 20.42 | 24 | 26.97 | 26.91 | 10.11 | 7.12 | |
Return on Capital Employed (%) | 37.54 | 65.86 | 28.87 | 22.15 | 22.66 | 23.3 | 26.28 | 11.25 | 7.44 | |
Return on Assets (%) | 17.47 | 32.07 | 14.97 | 12.25 | 13.15 | 14.37 | 16.95 | 7.34 | 5.15 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 885 | 1,597 | 1,902 | 2,220 | 2,719 | 3,219 | 5,067 | 5,238 | 4,370 | 4,470 | |
Non Curr. Liab. | 72 | 84 | 94 | 576 | 570 | 1,047 | 361 | 162 | 52 | 52 | |
Curr. Liab. | 908 | 944 | 814 | 1,267 | 1,664 | 1,954 | 1,533 | 1,831 | 1,641 | 1,810 | |
Minority Int. | 0 | 0 | -1 | -29 | |||||||
Equity & Liab. | 1,865 | 2,626 | 2,811 | 4,064 | 4,952 | 6,192 | 6,961 | 7,230 | 6,064 | 6,332 | |
Non Curr. Assets | 750 | 917 | 1,317 | 2,116 | 2,820 | 3,526 | 4,057 | 4,255 | 3,150 | 3,197 | |
Curr. Assets | 1,115 | 1,708 | 1,494 | 1,948 | 2,132 | 2,665 | 2,904 | 2,975 | 2,914 | 3,134 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 1,865 | 2,626 | 2,811 | 4,064 | 4,952 | 6,192 | 6,961 | 7,230 | 6,064 | 6,332 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 2,056 | 3,166 | 3,135 | 3,131 | 3,935 | 4,606 | 5,393 | 5,306 | 5,653 | 6,118 | |
Other Income | 12 | 9 | 3 | 35 | 27 | 14 | 87 | 50 | 3 | 26 | |
Total Income | 2,068 | 3,175 | 3,137 | 3,166 | 3,962 | 4,620 | 5,481 | 5,356 | 5,656 | 6,144 | |
Total Expenditure | -1,661 | -2,161 | -2,520 | -2,516 | -3,079 | -3,392 | -3,913 | -4,432 | -4,945 | -5,233 | |
PBIDT | 407 | 1,014 | 617 | 650 | 883 | 1,228 | 1,568 | 925 | 711 | 911 | |
Interest | -4 | -5 | -5 | -3 | -18 | -27 | -16 | -18 | -50 | -60 | |
Depreciation | -44 | -72 | -83 | -105 | -115 | -157 | -183 | -287 | -275 | -277 | |
Taxation | -76 | -216 | -122 | -120 | -157 | -199 | -253 | -104 | -13 | 25 | |
Exceptional Items | -44 | ||||||||||
PAT | 283 | 720 | 407 | 421 | 593 | 801 | 1,115 | 521 | 342 | 599 | |
Minority Interest | 0 | 0 | 1 | 28 | |||||||
Share Associate | 0 | -4 | -8 | -9 | 0 | 32 | -9 | ||||
Other Related Items | |||||||||||
Consolidated Net Profit | 283 | 720 | 403 | 413 | 584 | 829 | 1,147 | 521 | 342 | 590 | |
Adjusted EPS | 15 | 38 | 21 | 22 | 31 | 44 | 58 | 27 | 17 | 30 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 240 | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | |
Cash Fr. Inv. | -81 | -256 | -307 | -486 | -884 | -756 | -732 | -839 | -372 | -448 | |
Cash Fr. Finan. | -151 | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 | |
Net Change | 8 | 3 | 417 | -286 | -69 | 115 | -128 | 27 | -37 | 14 | |
Cash & Cash Eqvt | 24 | 27 | 439 | 153 | 84 | 199 | 72 | 98 | 61 | 75 |
Wed, 27 Mar 2024
Trading Window Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
Wed, 27 Mar 2024
Trading Window-XBRL Alembic Pharmaceuticals Limited has informed the Exchange about Closure of Trading Window |
Fri, 22 Mar 2024
Loss/Duplicate-Share Certificate-XBRL Alembic Pharmaceuticals Limited has informed the Exchange about Loss of share certificates |
Wed, 27 Mar 2024 |
Close Crossing Last Week High |
Opening at Low |
Closing Above Previous High |
Close Within 52 Week High Zone |
Close Above Last Week High |